Abstract: A communication method and apparatus are provided. The method includes: receiving first indication information from a network device, where the first indication information indicates a first dimension; receiving a downlink reference signal from the network device, where the downlink reference signal is determined based on the first dimension and an uplink reference signal; and determining channel information based on the downlink reference signal. In the method, the network device and a terminal device each bear a part of a calculation amount and a part of calculation complexity. Therefore, a calculation amount and calculation complexity of channel estimation independently performed by the network device or the terminal device can be reduced, a system latency can be further shortened, and a throughput of a communication system can be improved.

Abstract: Some embodiments provide a method for performing data traffic monitoring. The method processes a packet through a packet processing pipeline that includes multiple stages. At a filtering stage, the method tags the packet with a set of monitoring actions for subsequent stages to perform on the packet based on a determination that the packet matches a particular filter. For each stage of a set of packet processing stages subsequent to the filtering stage, the method (i) executes any monitoring actions specified for the stage to perform on the packet and (ii) sends the packet to a next stage in the packet processing pipeline.

Abstract: The present disclosure provides for multi-specific antibodies and antigen-binding fragments thereof that bind to human MUC1 and CD16A, pharmaceutical compositions comprising said antibodies, and use of the antibodies or the compositions for treating a disease, such as cancer.

Abstract: This application provides a channel measurement method and apparatus. The method includes: A terminal device obtains a first reference signal set and a second reference signal set, where the first reference signal set includes N first reference signals, the second reference signal set includes M second reference signals, and M and N are positive integers greater than or equal to 1. The terminal device may further perform channel measurement based on the first reference signal set to obtain first channel information, where a first dimension of the first channel information is less than a quantity of transmit antennas of a first device. The terminal device may further obtain second channel information based on the second reference signal set and the first channel information, where a first dimension of the second channel information is less than the quantity of transmit antennas of the first device.

Abstract: A bispecific or dual target CAR or CAR-T cells can be used to treat and/or prevent an autoimmune disease. The bispecific CAR may target CD19 and BCMA. The CAR may have a loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3?; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.

Abstract: Embodiments of this application provide a communication method and a communication apparatus. The method includes: A first communication apparatus receives a first indication parameter. There is a correspondence between the first indication parameter and first codeword-to-layer mapping. The first communication apparatus determines the first codeword-to-layer mapping based on the first indication parameter. Based on the method, in embodiments of this application, codeword-to-layer mapping can be dynamically adjusted and/or indicated. For example, a terminal device may use different codeword-to-layer mapping at different moments. For another example, different terminal devices may use different codeword-to-layer mapping at a same moment.

Abstract: The present invention provides a screening method for searching a component inhibiting or treating scleral thinning, and eyedrops that contain the active ingredient, and hence can inhibit excessive thinning of the sclera, and as a result, can treat a posterior segment eye disease associated with the scleral thinning. The problems are solved by eyedrops containing, as an active ingredient, a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway. The problems are solved by a screening method for a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an indicator, influence on scleral thinning in the cell.

Abstract: Provided herein are combination therapies for treating blood cancer, in particular, acute myeloid leukemia, by concurrently targeting Axl and BCL-2.

Abstract: The present invention provides a novel chimeric antigen receptor, comprising an antigen-binding region, a transmembrane domain, a costimulatory domain, an intracellular signaling domain, and an additional signaling region. The additional signaling region consists of a ?c chain or an intracellular region thereof. The present invention also provides an engineered immune cell comprising the novel chimeric antigen receptor of the present invention and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.

Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Abstract: Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellular signaling region consists of a co-stimulatory domain, a primary signal transduction domain, and a ?C chain or intracellular region thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a pharmaceutical composition thereof, and use of the engineered immune cell/pharmaceutical composition for treating cancers.

Abstract: Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.

Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.

Abstract: Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with NKG2A expression.

Abstract: The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.

Abstract: Provided is a chimeric antigen receptor, comprising a ligand-binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. The co-stimulatory domain comprises an intracellular region of an NK-activated receptor or a ligand thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a use thereof in treatment of diseases, such as cancers, autoimmune diseases, and infections.

Abstract: The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.

Abstract: Provided is an engineered immune cell. The cell expresses a chimeric antigen receptor comprising an antigen-binding region. The antigen-binding region comprises an anti-CD7 antibody, and the expression of endogenous CD7, at least one TCR/CD3 gene, and at least one MHC-II related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of diseases associated with CD7 expression.

Abstract: A device and a method for inhibiting thinning of a choroid. A choroidal thinning inhibiting device including a light source that emits violet light having a wavelength within a range from 360 nm to 400 nm, the choroidal thinning inhibiting device inhibiting thinning of a choroid by irradiation with the violet light. This device may further include a control mechanism that controls an irradiance and an irradiation time of the violet light, can be applied to ocular diseases selected from age-related macular degeneration, glaucoma, diabetic retinopathy, macular edema, eye strain, retinal vascular occlusion, triangle syndrome, central serous chorioretinopathy, retinitis pigmentosa, presbyopia, cataracts, and the like that are based on inadequate blood flow or reduced blood flow, and can be expected to prevent and treat such ocular diseases.

Abstract: A high-pressure fuel pump includes a drive shaft, and a vane pump and a plunger pump which are driven by the drive shaft. The vane pump is configured to supply pre-pressurized fuel to the plunger pump. The drive shaft includes a cam configured to drive a piston rod of the plunger pump such that the plunger pump alternately executes a fuel suction stroke and a fuel discharge stroke. The drive shaft further includes a shaft portion for driving a rotor of the vane pump. The vane pump is configured such that for each fuel suction stroke of the plunger pump the vane pump provides a fuel supply cycle that is advanced by a phase angle relative to the fuel suction stroke.